Safety Study Evaluating Twice-Daily Administration of Momelotinib in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sierra Oncology LLC - a GSK company
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of PMF or post-ET/PV MF as per revised World Health Organization (WHO) criteria (Section 16.4, Appendix 3).
High-risk or Intermediate-2 risk MF (as defined by the International Prognostic Scoring System \[IPSS\]; Section 16.6, Appendix 5); or Intermediate-1 risk MF (IPSS) associated with symptomatic splenomegaly/hepatomegaly and/or unresponsive to available therapy.
Must be at least 18 years of age with life expectancy of ≥ 12 weeks.
Must be able to provide informed consent and be willing to sign an informed consent form.
Must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2 (Section 16.3, Appendix 2).
Must have evidence of acceptable organ function within 7 days of initiating study drug as evidenced by the following:
AST or ALT less than or equal 2.5 x upper limit of normal (ULN) (or less than or equal to 5 x ULN if in the investigator's opinion the elevation is due to extramedullary hematopoiesis)
Direct Bilirubin less than or equal to 2.0 x ULN
Serum creatinine less than or equal to 2.5 x ULN
Absolute neutrophil count ≥ 500/µL
Platelet count ≥ 50,000/µL
Females of childbearing potential must have a negative pregnancy test within 4 days of initiating study drug.
You may not be if
Any chemotherapy (e.g., hydroxyurea), immunomodulatory drug therapy (e.g., thalidomide), immunosuppressive therapy, corticosteroids \>10 mg/day prednisone or equivalent, or growth factor treatment (e.g., erythropoietin) within 14 days prior to initiation of study drug.
Incomplete recovery from major surgery within four weeks of study entry.
Radiation therapy within four weeks of study entry.
Women of childbearing potential, unless surgically sterile for at least 3 months (i.e., hysterectomy), OR postmenopausal for at least 12 months (FSH \> 30 U/mL), OR unless they agree to take appropriate precautions to avoid pregnancy (with at least 99% certainty) from screening through end of study. Permitted methods for preventing pregnancy must be communicated to study subjects and their understanding confirmed.
Men who partner with a woman of childbearing potential, unless they agree to take appropriate precautions to avoid pregnancy (with at least 99% certainty) from screening through to the end of study. Permitted methods for preventing pregnancy must be communicated to study subjects and their understanding confirmed.
Females who are pregnant or are currently breastfeeding.
Known positive status for HIV.
Positive serologic testing for hepatitis B (HBsAg and HBcAb total) and hepatitis C (anti-HCV)
Diagnosis of another malignancy unless free of disease for at least three years following therapy with curative intent. Patients with early-stage basal cell or squamous cell skin cancer, cervical intraepithelial neoplasia, cervical carcinoma in situ or superficial bladder cancer may be eligible participate at the Investigator's discretion.
Any acute active infection.
Cardiac dysrhythmias requiring treatment, or prolongation of the QTc (Fridericia) interval to \>480 at pre-study screening, unless attributable to pre-existing bundle branch block.
Presence of ≥ grade 2 peripheral neuropathy.
Uncontrolled congestive heart failure (New York Heart Association Classification 3 or 4), uncontrolled or unstable angina, myocardial infarction, cerebrovascular accident, or pulmonary embolism within 3 months prior to initiation of study drug.
Uncontrolled intercurrent illness or any concurrent condition that, in the Investigator's opinion, would jeopardize the safety of the patient or compliance with the protocol.
Clareo Health | Safety Study Evaluating Twice-Daily Administration of Momelotinib in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis
